Company profile for Evgen Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Evgen is a clinical stage drug development company focussed on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation. We have a comprehensive intellectual property package over this technology, covering novel compositions and manufacturing methods. Our pipeline exploits sulforaphane’s activity in two separate biochemical pat...
Evgen is a clinical stage drug development company focussed on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation. We have a comprehensive intellectual property package over this technology, covering novel compositions and manufacturing methods. Our pipeline exploits sulforaphane’s activity in two separate biochemical pathways; inhibition of pSTAT3, of importance in controlling cancer metastases, and up-regulation of Nrf2, a therapeutic target associated with a broad range of diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
Evgen Pharma The Colony Altrincham Road Wilmslow
Telephone
Telephone
+44 (0) 1625 466591
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmatimes.com/news/evgen_completes_three_cohorts_for_sfx-01_1485814

PHARMATIMES
25 Jan 2023

https://www.pharmatimes.com/news/evgen_to_investigate_new_sfx-01_tablet_formulation_1480820

PHARMATIMES
16 Nov 2022

https://www.pharmatimes.com/news/regulatory_approval_received_for_evgens_sfx-01_study_1456090

PHARMATIMES
29 Sep 2022

https://www.pharmaceutical-technology.com/news/evgen-colorectal-cancer-asset/

PHARMACEUTICAL-TECHNOLOGY
14 Jun 2022

https://www.sharesmagazine.co.uk/news/market/LSE20211110070006_4172852/Publication-of-data-on-SFX-01-in-glioblastoma

SHARESMAGAZINE
10 Nov 2021

https://www.investegate.co.uk/evgen-pharma-plc--evg-/rns/publication-of-data-in-glioblastoma-cells/202109200700091988M/

INVESTEGATE
20 Sep 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty